# MUCOSAL IMMUNE RESPONSE TO RESPIRATORY SYNCYTIAL VIRUS

> **NIH NIH R01** · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 1989 · $175,820

## Abstract

The studies proposed for the competitive renewal period will
focus on three major areas of immune response to RSV in man and
in experimental animal models.  These include human studies on
the role of immune response in the natural history and outcome of
naturally acquired RSV infection.  1) It is planned to determined
the nature and possible role of immune response to major
glycoproteins of RSV (especially F and G) in various
immunoglobulin isotypes in serum and secretions over the course
of the RSV induced bronchiolitis and wheezing.  Studies will be
undertaken to examine the effect of treatment with ribavirin, an
antiviral chemotherapeutic agent, on the development of IgE
specific antibody response to RSV glycoproteins and on the
outcome of RSV associated wheezing.  The role of possible release
of LTC4 and LTD4 in the pathogenesis of virus induced wheezing
will also be studied.  2) Other studies are proposed to examine the
mechanisms of immunopathology of RSV infection in
experimentally induced pulmonary disease in BALB/c mice.  If is
hoped to define virus and host related determinants of lung
disease in animals who had been previously immunized with
parenterally administered RSV.  These studies will also attempt to
examine the influence of RSV infection on the uptake of other
environmental antigens or dietary macromolecules available in
the respiratory tract.  3) Finally, long term studies are planned to
explore alternative approaches to the development of
immunoprophylaxis against RSV.  Studies will be carried out to
determine the effectiveness of intestinal immunization with RSV
or RSV glycoproteins in inducing RSV specific immunologic
reactivity in the respiratory tract and in protection against
respiratory reinfection challenge.  It is also planned to determine
if immunization with isolated glycoproteins rather than whole
virus will selectively limit or prevent development or RSV
specific IgE response during primary immunization and during
subsequent reinfection challenge.  These investigations will
involve routine tissue culture, immunofluorescence, Elisa and
conventional immunologic procedures currently used in our
laboratory.

## Key facts

- **NIH application ID:** 3126492
- **Project number:** 5R01AI015939-10
- **Recipient organization:** STATE UNIVERSITY OF NEW YORK AT BUFFALO
- **SAM.gov UEI:** LMCJKRFW5R81
- **Principal Investigator:** PEARAY L OGRA
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1989
- **Award amount:** $175,820
- **Award type:** 5
- **Project period:** 1979-09-30 → 1993-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3126492

## Citation

> US National Institutes of Health, RePORTER application 3126492, MUCOSAL IMMUNE RESPONSE TO RESPIRATORY SYNCYTIAL VIRUS (5R01AI015939-10). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3126492. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*